FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is a pharmaceutical composition exhibiting anti-tumor activity and containing as active compounds 2-amino-7-(diethylamino)-4-(4-methoxybenzo[d][1,3]dioxol-5-yl)-4H-chromene-3-carbonitrile (compound 1) or 2-aminium-7-(diethylamino)-4-(4-methoxybenzo[d][1,3]dioxol-5-yl)-4H-chromene-3-carbonitrile N-acetylaminoethanoate (compound 2) and pharmaceutically acceptable excipients in following ratio of components, wt %: active substance (compound 1 or 2) 5.0–30.0; pregelatinised corn starch 10.0–50.0; microcrystalline cellulose 5.0–60.0; colloidal silicon dioxide 1.0–5.0; stearic acid 0–1.0; sodium dodecyl sulphate 0–3.0; kollidone VA 64 0–3.0; Polysorbate 80 (Tween 80) 0–3.0.
EFFECT: technical result is obtaining low-toxic pharmaceutical compositions with anti-tumor activity based on compounds 1 or 2.
1 cl, 18 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION WITH ANTIARRHYTHMIC ACTIVITY OF VARIOUS ETIOLOGIES | 2021 |
|
RU2783944C1 |
2-AMINIUM-7-(DIETHYLAMINO)-4-(4-METHOXIBENZO[D][1,3]DIOXOL-5-YL)-4H-CHROMEN-3-CARBONITRILE N-ACETYLAMINOETHANOAT HAVING ANTITUMOR ACTIVITY | 2018 |
|
RU2674987C1 |
NEW 9-AMINOACRIDONE DERIVATIVE WITH ANTITUMOR AND ANTIMETASTATIC ACTIVITY | 2021 |
|
RU2810783C2 |
ORAL FORM OF GESTAGEN-CONTAINING COMPOSITION FOR TREATING WOMEN WITH CONDITIONS OF GESTAGEN INSUFFICIENCY AND METHOD FOR PREPARING IT | 2018 |
|
RU2684917C1 |
ANTITUMOUR AGENT FOR TREATING PROSTATE CANCER IN THE FORM OF SACHET | 2018 |
|
RU2695326C1 |
PHARMACEUTICAL COMPOSITION BASED ON PALLADIUM COMPOUND | 2015 |
|
RU2613305C2 |
SOLUTION THAT HAVE ANTIPROLIFERATIVE AND ANTIMETASTATIC PROPERTIES FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2678769C2 |
PHARMACEUTICAL COMPOSITION BASED ON N-BENZYL-N-METHYL-1-PHENYLPYRROLO [1,2-A] PYRAZINE-3-CARBOXAMIDE | 2017 |
|
RU2689396C2 |
MEDICATION POSSESSING HAEMOSTIMULATING, ANTIMUTAGENIC, ANTITUMOUR, CEREBROPROTECTIVE, ANTIHYPOXIC, NOOTROPIC, ANXIOLYTIC AND ANTINEUROTIC ACTION | 2010 |
|
RU2438691C1 |
ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
Authors
Dates
2019-10-25—Published
2018-12-27—Filed